
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **September 3, 2002**

IDEC PHARMACEUTICALS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

0-19311
(Commission File Number)

33-0112644
(IRS Employer Identification No.)

3030 Callan Road, San Diego, CA
(Address of principal executive offices)

92121
(Zip Code)

Registrant's telephone number, including area code: **(858) 431-8500**

N/A
(Former name or former address, if changed since last report)

ITEM 5. Other Events.

Nabil Hanna, the company's chief scientific officer, has informed us that he has established a non discretionary sales plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 in order to gradually diversify his holdings. The sales plan takes effect September 8, 2003 and expires December 31, 2004. The sales plan provides for sales of up to 150,000 shares per three month period depending on prevailing market prices. The maximum number of shares which can be sold under the sales plan is 313,600.

ITEM 7. Financial Statements and Exhibits.

(a)

Financial Statements

None.

(b)

Pro Forma Financial Statements

None.

(c)

Exhibits

None.

2

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 3, 2003

IDEC PHARMACEUTICALS CORPORATION

By /s/ JOHN M. DUNN

Name: John M. Dunn
Title: Senior Vice President and General Counsel

3
